Dr. Matthew Pullen earned his degree from this campus - the University of Tennessee at Chattanooga - in molecular biology.
He is now at the University of Minnesota’s Department of Medicine - and one of the researchers behind a study published last month in The New England Journal of Medicine on hydroxycholorquine.
The prescription drug successfully treats lupus, rheumatoid arthritis and malaria.
Dr. Pullen and colleagues at three universities in Canada ran the first randomized clinical trial of the drug after exposure from the coronavirus - and found it was not effective in slowing down the replication of the virus.
Credit UTC
